Scholar Rock Holding Corporation

NasdaqGS SRRK

Scholar Rock Holding Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -1,959.82%

Scholar Rock Holding Corporation EBITDA Margin is -1,959.82% for the Trailing 12 Months (TTM) ending September 30, 2024, a -304.63% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Scholar Rock Holding Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -484.35%, a -42.77% change year over year.
Scholar Rock Holding Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -339.25%, a 47.86% change year over year.
Scholar Rock Holding Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -650.67%, a -76.69% change year over year.
Scholar Rock Holding Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -368.25%, a 15.94% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: SRRK

Scholar Rock Holding Corporation

CEO	Dr. Jay Thomas Backstrom M.D., M.P.H.
IPO Date	May 25, 2018
Location	United States
Headquarters	301 Binney Street
Employees	150
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years